Common cold in past may provide protection from COVID-19: Study

By: |
September 30, 2020 5:56 PM

Because memory B cells can survive for decades, they could protect COVID-19 survivors from subsequent infections for a long time, but further research will have to confirm this.

coronavirus mumbaiRepresentational image

People who have had a bout of seasonal or common cold in the past may get some protection from COVID-19, according to a study which suggests that immunity to the disease is likely to last a long time — maybe even a lifetime.

The study, published in the journal mBio, is the first to show that the COVID-19-causing virus, SARS-CoV-2, induces memory B cells, long-lived immune cells that detect pathogens, create antibodies to destroy them and remember them for the future.

The next time that pathogen tries to enter the body, those memory B cells can hop into action even faster to clear the infection before it starts, according to the researchers from the University of Rochester Medical Center (URMC) in the US.

Because memory B cells can survive for decades, they could protect COVID-19 survivors from subsequent infections for a long time, but further research will have to confirm this.

The study is also the first to report cross-reactivity of memory B cells — meaning B cells that once attacked cold-causing coronaviruses appeared to also recognise SARS-CoV-2.

The researchers believe this could mean that anyone who has been infected by a common coronavirus — which is nearly everyone — may have some degree of pre-existing immunity to COVID-19.

“When we looked at blood samples from people who were recovering from COVID-19, it looked like many of them had a pre-existing pool of memory B cells that could recognise SARS-CoV-2 and rapidly produce antibodies that could attack it, said study lead author Mark Sangster, a research professor at URMC.

The findings are based on a comparison of blood samples from 26 people who were recovering from mild to moderate COVID-19 and 21 healthy donors whose samples were collected six to 10 years ago — long before they could have been exposed to COVID-19.

From those samples, the researchers measured levels of memory B cells and antibodies that target specific parts of the Spike protein, which exists in all coronaviruses and is crucial for helping the viruses infect cells.

The Spike protein looks and acts a little different in each coronavirus, but one of its components, the S2 subunit, stays pretty much the same across all of the viruses.

Memory B cells can’t tell the difference between the Spike S2 subunits of the different coronaviruses and attack indiscriminately, the researchers said.

They found that was true for beta-coronaviruses, a subclass that includes two cold-causing viruses as well as SARS, MERS and SARS-CoV-2.

What this study doesn’t show is the level of protection provided by cross-reactive memory B cells and how it impacts patient outcomes, according to the researchers said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Delhi sees another record coronavirus cases with over 5,700; AAP govt cites new strategy leading to rise
2Andhra Pradesh Unlock guidelines: Schools, colleges to open in phased manner from November 2 — check details
3Social gatherings in festivities, poor air quality among reasons for COVID cases rise in Delhi: Govt